Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

SGLT-2 inhibitors market to hit $32.16B by 2033, fueled by rising diabetes, CKD & heart failure cases; USA & Japan drive regional growth. The SGLT-2 inhibitors market will grow from US$ 17.95B in ...

A new study published in the Journal of American Medical Association showed that the usage of sodium-glucose cotransporter 2 ...

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

In elderly patients 65 years of age or older with heart failure with reduced ejection fraction (HFrEF), regular use of sodium ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in ...

In addition newer drugs like SGLT2 inhibitors, Angiotensin receptor neprisilyn inhibitors ,beta, blockers ,mineralocorticoid ...

Dapagliflozin reduced the risk of all-cause mortality or worsening heart failure by 28% in patients with aortic stenosis ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.